New Pancreatic Cancer Research from Ohio State University Outlined (FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer).

Předmět:	FIBROBLAST growth factor receptors PANCREATIC cancer CELL-free DNA REPORTERS & reporting PANCREATIC duct
Zdroj:	Clinical Oncology Week; 10/8/2024, p1084-1084, 1p
Abstrakt:	A recent study conducted at Ohio State University has identified a potential subgroup of pancreatic cancer patients who may benefit from targeted therapies. The research focused on genomic alterations in fibroblast growth factor receptor (FGFR) genes and found that FGFR2 fusions were present in a small number of metastatic pancreatic ductal adenocarcinomas (PDAC). The study observed durable responses or disease control in four FGFR2 fusion-positive PDAC patients who were treated with FGFR kinase inhibitors. These findings provide clinical evidence for the identification and treatment of FGFR2 fusion-positive PDAC patients with FGFR targeted therapy. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu